Editorial advisory board member

Date: May 2, 2017

Contact information

Name: Muhammad Mamdani
Affiliations:
- Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada;
- Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada;
- Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada;
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada;
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada;

Biographical details

Muhammad Mamdani, PharmD, MA, MPH
Director – Li Ka Shing Centre for Healthcare Analytics Research and Training (CHART)
Li Ka Shing Knowledge Institute of St. Michael's Hospital; Professor, University of Toronto

Dr. Mamdani is the Director of the Li Ka Shing Centre for Healthcare Analytics Research and Training (CHART) of the Li Ka Shing Knowledge Institute of St. Michael's Hospital in Toronto. He is also Professor in the Leslie Dan Faculty of Pharmacy, the Department of Medicine of the Faculty of Medicine, and the Institute of Health Policy, Management and Evaluation of the Dalla Lana Faculty of Public Health. He is also adjunct Senior Scientist at the Institute for Clinical Evaluative Sciences (ICES). Dr. Mamdani also is a member of the Human Drug Advisory Panel of the Patented Medicine Prices Review Board (PMPRB) and is a co-Principal Investigator of the Ontario Drug Policy Research Network. In 2010, Dr. Mamdani was named among Canada's Top 40 under 40. Prior to joining the Li Ka Shing Knowledge Institute and St. Michael's Hospital, Dr. Mamdani was a Director of Outcomes Research at Pfizer Global Pharmaceuticals in New York. Dr. Mamdani's research interests include pharmacoepidemiology, pharmacoconomics, and drug policy. He has published approximately 400 research studies in peer-reviewed medical journals, including leading journals such as the New England Journal of Medicine, the Lancet, the Journal of the American Medical Association, the British Medical Journal, and Annals of Internal Medicine.
Dr. Mamdani obtained a Doctor of Pharmacy degree (PharmD) from the University of Michigan (Ann Arbor) in 1995 and subsequently completed a fellowship in pharmacoconomics and outcomes research at the Detroit Medical Center in 1997. During his fellowship, Dr. Mamdani obtained a Master of Arts degree in Economics from Wayne State University in Detroit, Michigan. He then completed a Master of Public Health degree from Harvard University in 1998 with a concentration in quantitative methods, focusing on biostatistics and epidemiological principles.

Declaration of competing interests

All questions relate to the past 3 years (inclusive):

1. Have you accepted any of the following from an organization that has (or might have) a relationship with CMA/now or in the future and that might gain or lose financially because of the relationship?

   a. Reimbursement for attending a symposium
      Details if yes:
      ☑ Yes ☐ No

   b. Speaker fees
      Details if yes:
      ☐ Yes ☑ No

   c. Fees for educational event
      Details if yes:
      ☐ Yes ☑ No

   d. Research funds
      Details if yes:
      ☐ Yes ☑ No

   e. Funds for a member of your staff
      Details if yes:
      ☑ Yes ☐ No

   f. Consulting fees
      Details if yes:
      ☑ Yes ☐ No

Muhammad Mamdani reports receiving honoraria for serving on ad hoc advisory boards for Allergan, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Hoffman-La Roche, Novartis, Novo Nordisk, and Pfizer.

2. Do you hold stocks or shares in an organization that might benefit or lose from an existing relationship with CMA?
   Details if yes:
   ☑ Yes ☐ No

3. Do you have other competing financial interests?
   Details if yes:
   ☑ Yes ☐ No

4. I have the following other competing interests (details):
<table>
<thead>
<tr>
<th>Signature</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>May 2, 2017</td>
</tr>
</tbody>
</table>